2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. c-Met/HGFR

c-Met/HGFR

c-Met/HGFR

Related Products

PDF 1.01 MB

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152849A
    Boditrectinib oxalate
    		Inhibitor
    Boditrectinib oxalate is a potent tyrosine kinase inhibitor. Boditrectinib oxalate serves as an antineoplastic agent. Boditrectinib oxalate is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Boditrectinib oxalate
  • HY-148793
    Resencatinib
    		Inhibitor
    Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity. Resencatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Resencatinib
  • HY-P990949
    Umikibart
    HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Umikibart
  • HY-14721A
    Tepotinib hydrochloride
    		Inhibitor
    Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects.
    Tepotinib hydrochloride
  • HY-162803
    c-Met-IN-24
    		Inhibitor
    c-Met-IN-24 (compound 3g) is a dual-target inhibitor of STAT-3 (=4.7 μM) and c-MET (=12.67 μM) with anticancer activity. c-Met-IN-24 arrests the G2/M cell cycle and induces apoptosis in SNB-75 cells. c-Met-IN-24 can be used in the study of central nervous system cancers.
    c-Met-IN-24
  • HY-120908
    c-Met-IN-16
    		Inhibitor
    c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research.
    c-Met-IN-16
  • HY-148279
    c-Met-IN-15
    		Inhibitor 98.50%
    c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM.
    c-Met-IN-15
  • HY-123237
    KRC-108
    		Inhibitor
    KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice.
    KRC-108
  • HY-168268
    c-Met-IN-26
    		Inhibitor
    c-Met-IN-26 (compound 1-170) is a potent inhibitor of c-Met, with the IC50 of 1.6 nM. c-Met-IN-26 palys an important role in cancer research.
    c-Met-IN-26
  • HY-155544
    Antitumor agent-111
    		Inhibitor
    Antitumor agent-111 (compound 46) is an c-Met kinase inhibitor (IC50=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis.
    Antitumor agent-111
  • HY-163006
    EGFR/c-Met-IN-1
    		Inhibitor
    EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of EGFR/c-Met. The IC50 for inhibiting EGFRL858R and c-Met is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo.
    EGFR/c-Met-IN-1
  • HY-101031
    c-Met-IN-1
    		Inhibitor
    c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity..
    c-Met-IN-1
  • HY-50878AS
    Crizotinib-d9 hydrochloride
    		Inhibitor
    Crizotinib-d9 hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition.
    Crizotinib-d<sub>9</sub> hydrochloride
  • HY-157519
    LAH-1
    		Inhibitor
    LAH-1 is a c-Met inhibitor with oral activity and membrane permeability with an IC50 of 49 nM. LAH-1 has anticancer activity and can induce apoptosis, migration, and invasion.
    LAH-1
  • HY-157387
    c-Met-IN-22
    		Inhibitor
    c-Met-IN-22 (compound 51am) is an orally active inhibitor against c-Met with an IC50 value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis.
    c-Met-IN-22
  • HY-171191
    REGN5093-M114
    REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528).
    REGN5093-M114
  • HY-155812
    Tyrosine kinase-IN-6
    		Inhibitor
    Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects.
    Tyrosine kinase-IN-6
  • HY-118269
    OSI-296
    		Inhibitor
    OSI-296 is a potent, oral and selective inhibitor of cMET and RON kinases. OSI-296 shows in vivo efficacy in MKN45 tumor xenografts models and well tolerated.
    OSI-296
  • HY-162773
    MET-IN-1
    		Inhibitor
    MET-IN-1 (Compound 13) is an orally active MET inhibitor. MET-IN-1 has antitumor activity.
    MET-IN-1
  • HY-174384
    MET Transcription-IN-1
    		Inhibitor
    MET Transcription-IN-1 (Compound C3) is an orally active MET transcription inhibitor. MET Transcription-IN-1 can efficiently bind and stabilize the G-quadruplex in the MET promoter region, thereby inhibiting c-Met expression. MET Transcription-IN-1 can also overcome drug resistance caused by specific c-Met mutations. MET Transcription-IN-1 is capable of inhibiting tumor cell proliferation, migration, and invasion, as well as inducing cell cycle arrest and apoptosis. MET Transcription-IN-1 has antitumor activity, and can be used in the research of tumors such as non-small cell lung cancer.
    MET Transcription-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity